MedTrace Logo

B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes

NCT03327571 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1770

Last updated 2021-06-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to describe progression-free survival (PFS) in participants with relapsed or refractory classical Hodgkin lymphoma (RRHL), defined as the time from initiation of first treatment for RRHL to first documentation of relapse or disease progression, or death.

Conditions

  • Classical Hodgkin Lymphoma
  • Relapsed or Refractory Classical Hodgkin Lymphoma

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Takeda

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-21
Primary Completion
2019-10-31
Completion
2019-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03327571 on ClinicalTrials.gov